Compare IIIV & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IIIV | EMBC |
|---|---|---|
| Founded | 2012 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.9M | 524.1M |
| IPO Year | 2018 | 2021 |
| Metric | IIIV | EMBC |
|---|---|---|
| Price | $22.55 | $3.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $33.20 | $18.50 |
| AVG Volume (30 Days) | 293.3K | ★ 626.3K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 6.88% |
| EPS Growth | N/A | ★ 20.90 |
| EPS | 0.02 | ★ 0.74 |
| Revenue | N/A | N/A |
| Revenue This Year | $9.05 | $1.17 |
| Revenue Next Year | $8.07 | N/A |
| P/E Ratio | $1,165.50 | ★ $12.55 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.89 | $8.47 |
| 52 Week High | $33.97 | $15.55 |
| Indicator | IIIV | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 53.75 | 14.86 |
| Support Level | $22.12 | N/A |
| Resistance Level | $23.52 | $9.54 |
| Average True Range (ATR) | 0.94 | 0.38 |
| MACD | 0.19 | -0.32 |
| Stochastic Oscillator | 55.49 | 0.93 |
i3 Verticals Inc provides mission-critical enterprise software solutions to public sector entities. These comprehensive cloud-native solutions address a broad range of government functions, including courts and public safety, public administration, utilities, transportation and schools. The company generates the majority of revenue from software and related services, including the sale of subscriptions, recurring services, ongoing support, licenses, and installation and implementation services specific to software.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.